| 摘要 |
FIELD: medicine, pharmaceutics.SUBSTANCE: what is presented is a group of inventions involving a method and a pharmaceutical composition for reducing cardiotoxicity and/or improved survival rate after antracycline chemotherapy. A therapeutically effective amount of a pharmaceutical composition containing a compound representing Vselective vasopressin antagonist as an active ingredient, or its pharmaceutically acceptable salt as an active ingredient is introduced simultaneously with or before the introduction of antracycline in a patient in need thereof.EFFECT: invention provides reduced cardiotoxicity of antracyclines in reduced side effects ensured by a decreased level of serum vasopressin the abnormal content of which is typical for the patients suffering cancer, and which in turn is of paramount importance in developing congestive heart failure.15 cl, 5 ex, 2 tbl |
